Premium
Biomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand
Author(s) -
Kulhari Hitesh,
Pooja Deep,
Rompicharla Sri V. K.,
Sistla Ramakrishna,
Adams David J.
Publication year - 2015
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21345
Subject(s) - trastuzumab , metastatic breast cancer , breast cancer , monoclonal antibody , cancer , ligand (biochemistry) , cancer research , medicine , targeted therapy , drug delivery , pharmacology , targeted drug delivery , epidermal growth factor receptor , drug , chemistry , receptor , antibody , immunology , organic chemistry
Abstract Trastuzumab (TZ) is a humanized monoclonal antibody targeted to the extracellular domain of human epidermal growth factor receptor 2 (HER2), a tyrosine kinase receptor. TZ is approved by the Food and Drug Administration (FDA) for the treatment of HER2‐overexpressing early stage and metastatic breast cancer and HER2‐overexpressing metastatic gastric cancer. For breast cancer, it is recommended as both a single agent and in combination with standard chemotherapy. In the last few years, TZ has also been used as a targeting ligand. Overexpression of HER2 in breast cancer and the presence of free surface functional groups on TZ provide an opportunity to use it as a targeting ligand. TZ can be conjugated to various nanoparticulate systems such as dendrimers, polymeric, and protein nanoparticles to target drug delivery. TZ‐conjugated inorganic nanoparticles have been reported for imaging and diagnostic purposes. This review summarizes the applications of TZ both as a therapeutic agent and as a targeting ligand.